Acadian Asset Management
PRLD icon

Acadian Asset Management’s Prelude Therapeutics PRLD Stock Holding History

Acadian Asset Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
611,359
+99,840
+20% +$435K ﹤0.01% 924
2026
Q1 		$1.75M Sell
511,519
-24,184
-5% -$63.4K ﹤0.01% 998
2025
Q4 		$1.55M Sell
535,703
-4,862
-0.9% -$8.21K ﹤0.01% 985
2025
Q3 		$777K Hold
540,565
– – ﹤0.01% 1115
2025
Q2 		$436K Buy
540,565
+11,238
+2% +$9.73K ﹤0.01% 1166
2025
Q1 		$405K Buy
529,327
+43,946
+9% +$41K ﹤0.01% 1117
2024
Q4 		$617K Buy
485,381
+411,238
+555% +$546K ﹤0.01% 1032
2024
Q3 		$152K Buy
74,143
+52,033
+235% +$241K ﹤0.01% 1459
2024
Q2 		$83K Hold
22,110
– – ﹤0.01% 1559
2024
Q1 		$104K Buy
22,110
+6,615
+43% +$25.7K ﹤0.01% 1281
2023
Q4 		$65K Buy
15,495
+8,472
+121% +$25.8K ﹤0.01% 1428
2023
Q3 		$21K Buy
+7,023
New +$26.4K ﹤0.01% 1540

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Acadian Asset Management's PRLD Position: Q2 2026 in Review

Acadian Asset Management increased its Prelude Therapeutics (PRLD) stake by 20% in Q2 2026, buying an estimated $435K and bringing the position to 611,359 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #924.

Acadian Asset Management first reported a position in PRLD in Q3 2023 and has held it in 12 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Acadian Asset Management held 611,359 shares of Prelude Therapeutics worth $3.25M as of Q2 2026.
  • Acadian Asset Management bought 99,840 Prelude Therapeutics shares in Q2 2026, an estimated $435K.
  • Prelude Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #924 holding.
  • Acadian Asset Management first reported a position in Prelude Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.